As the 2021 virtual J.P. Morgan Healthcare Conference wrapped up, BioSpace reviewed news from companies regarding their deals, pipeline and regulatory updates.

Precision Medicine Group acquired Project Farma, a patient-focused bioengineering services firm that supports life science innovators in the manufacturing and scale-up of advanced therapies.

Urovant Sciences and Genmab reported disappointing clinical trial announcements.

Biomarkers will be critical to developing precision medicine for Alzheimer’s disease, and phosphorylated tau (P-tau) may enable earlier and more accurate detection, according to Eli Lilly-associated researchers.

Researchers with Pfizer and IBM developed an artificial intelligence (AI) model that they claim can predict the eventual onset of Alzheimer’s disease with 71% accuracy based on a language sample.

Beckman Coulter will be using a grant from BARDA (the Biomedical Advanced Research and Development Authority, a division of the Dept. of Health and Human Services) to validate the ability of the company’s Monocyte Distribution Width (MDW) hematology biomarker to aid in the rapid detection of a rare but serious complication of Covid-19 affecting children. 

Researchers from Aarhus University in Denmark published research indicating that Parkinson’s disease is actually two types of the disease.

Progentec Diagnostics Inc. launched a novel blood test to determine the likelihood that a patient with systemic lupus erythematosus (commonly known as both SLE and lupus) will experience an immunologic disease flare during the coming 12 weeks.

AstraZeneca and Merck announced positive five-year follow-up data from the Phase III SOLO-1 trial which demonstrated a long-term progression-free survival benefit of Lynparza as a first-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who were in complete or partial response to platinum-based chemotherapy.

Eli Lilly announced interim proof-of-concept data from the company’s BLAZE-1 Phase II clinical trial of LY-COV555, a neutralizing antibody therapy for Covid-19.